A blockbuster #preprint of #LongCovid from UK; 1077 patients discharged in 2020; at median 5 mos only 29% fully recovered, 20% had new disability. medrxiv.org/content/10.110… @medrxivpreprint @REvans_Breathe @uol3i @HamishMcAuley @LouiseVwain @Survivor_Corps @patientled @dianaberrent Image
@medrxivpreprint @REvans_Breathe @uol3i @HamishMcAuley @LouiseVwain @Survivor_Corps @patientled @dianaberrent And another indicator of the impact of #COVID19… at a median of 5 months after hospital discharge, 19% experienced a health-related change in occupation. @medrxivpreprint Image
@medrxivpreprint @REvans_Breathe @uol3i @HamishMcAuley @LouiseVwain @Survivor_Corps @patientled @dianaberrent "Factors associated with failure to recover were female, middle-age, white ethnicity, two or more co-morbidities, and more severe acute illness.” Image
@medrxivpreprint @REvans_Breathe @uol3i @HamishMcAuley @LouiseVwain @Survivor_Corps @patientled @dianaberrent “The 10 most commonly reported symptoms: ‘aching...muscles (pain)’, ‘fatigue’, ‘physical slowing down’, ‘impaired sleep quality’, ‘joint pain or swelling’, ‘limb weakness’, ‘breathlessness’, ‘pain’, ‘short-term memory loss’ & ‘slowing down in ...thinking’.” @medrxivpreprint
@medrxivpreprint @REvans_Breathe @uol3i @HamishMcAuley @LouiseVwain @Survivor_Corps @patientled @dianaberrent Important that this prospective study had some selection: 'This analysis is restricted to participants who consented to attend two follow-up research visits within one-year post-discharge in addition to routine clinical care.’
@medrxivpreprint @REvans_Breathe @uol3i @HamishMcAuley @LouiseVwain @Survivor_Corps @patientled @dianaberrent "At least a fifth reached the threshold for a new disability with >= 1 domain coded as “a lot of difficulty” or “cannot do it all”… 56.2%, 48.1%, 41.8%, and 38.7% of the cohort reported significant worse symptoms of fatigue, breathlessness, sleep, and pain, respectively."
@medrxivpreprint @REvans_Breathe @uol3i @HamishMcAuley @LouiseVwain @Survivor_Corps @patientled @dianaberrent They identified 4 clusters of #LongCovid 1: v severe mental & physical health impairment (17%); 2 severe mental & physical health impairment (21%);3 mod mental & physical health impairment w/pronounced cognitive impairment; 4: mild mental & physical health impairment (46%). Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Harlan Krumholz

Harlan Krumholz Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @hmkyale

23 Mar
And here is another important #longCOVID #preprint by the amazing @NatalieJLambert and team. "most common symptoms were fatigue, headache, shortness breath, difficulty concentrating, cough, changed sense taste, diarrhea, & muscle aches." medrxiv.org/content/10.110… @medrxivpreprint
@NatalieJLambert @medrxivpreprint "Symptoms causing greatest distress (scale 1 “none” to 5 “great deal”) were extreme pressure at base of head (4.4), syncope (4.3), sharp or sudden chest pain (4.2), brain pressure (4.2), headache (4.2), persistent chest pain or pressure (4.1), and bone pain in extremities (4.1)."
@NatalieJLambert @medrxivpreprint Again, we see a remarkable range of downstream symptoms from COVID; this illness has devastating consequences for so many that extends far beyond the acute illness. Much to learn. Need to move quickly. @Survivor_Corps @dianaberrent
Read 5 tweets
23 Mar
Striking #preprint on #LongCovid: 'high rates of long-term symptoms and poor long-term outcomes, present several months after hospitalisation for #Covid19’ Over 50% with symptoms months later. A quarter w/new or worse disability. medrxiv.org/content/10.110… @medrxivpreprint
@medrxivpreprint So useful: ‘>half of patients reported not being fully recovered 7 mos after onset Covid-19 symptoms.’ 'Younger women &those w/more severe acute disease in-hospital had worst long-term outcomes.’ @dianaberrent @ahandvanish @louise_sigfrid @JTSglobalhealth @Tom_Drake1 @tweediechap
@medrxivpreprint @dianaberrent @ahandvanish @louise_sigfrid @JTSglobalhealth @Tom_Drake1 @tweediechap They conclude: 'Policymakers need ensure there is long-term support for people experiencing #LongCovid & plan for lasting long-term population morbidity. Funding to understand mechanisms and identify potential interventions for testing in randomised trials is urgently required.'
Read 6 tweets
26 Dec 20
Worth your time to take a look at @EdwardTufte new book: Seeing with Fresh Eyes: Meaning, Space, Data, Truth. He is a visionary warrior fighting for clarity in visual communication. Has always inspired me. edwardtufte.com/tufte/seeing-w…
@EdwardTufte From @EdwardTufte: “Conventions (We’ve always done it this way) enshired in leagacy code caused 50 years of content-hostile and reader-inconvenient data graphics in powerpoint, excel, and sophisticated data-analysis computer packages."
@EdwardTufte From @EdwardTufte: ‘Electronic health records seize ownership of medical information. Medical center business plans = own the data, own the patient.’ ‘Medical centers…intimidate patients to sign gag orders seizing ownership of all records.' @ePatientDave @TheLizArmy @myopennotes
Read 4 tweets
4 Oct 20
Very interested in @Regeneron therapy…2 non-competing neutralizing antibodies…one to receptor binding domain of the spike protein and one to the ACE receptor. They reported out early interim results for treatment of symptomatic people. Other studies pending Image
@Regeneron Inclusion criteria for the @Regeneron study was adult, non-hospitalized, symptoms <=7d, SARS-CoV-2 confirmed, and not on other COVID-19 therapies. Mean age was 44y. Half male. 42% obese. 7% (20 people) in the reported group were 65y and older.
@Regeneron The antibody cocktail to SARS-CoV-2 had a greater reduction in viral load for those whose viral load was higher at baseline. Image
Read 9 tweets
24 Sep 20
On the #COVID19 transparency front: JNJ has announced that they will share the Clinical Study Report and clinical trial participant data from their vaccine trial with researchers through @Yale Open Data Access (YODA) Project. @YaleMed @jsross119 @JNJNews jnj.com/coronavirus/le…
@Yale @YaleMed @jsross119 @JNJNews To provide context for the JNJ vaccine data sharing, @Yale YODA Project provides access to data to researchers w/ credible scientific proposal, agreement to report results, & commitment to protect participant privacy. Access decision is independent. yoda.yale.edu
@Yale @YaleMed @jsross119 @JNJNews To date, @Yale Open Data Access (YODA) Project has resulted in 42 submitted publications (31 published) based on JNJ participant-level data sharing. JNJ (Janssen) has committed to sharing data from all their drug and device trials through the YODA project. jnj.com/coronavirus/ou…
Read 6 tweets
16 Sep 20
Worth reading, policymakers please take note. “Vaccine hesitancy: why American values matter” The argument for transparency and independent evaluation in vaccine evaluation. Brillant and needed piece by @davidbeier1747 @LawrenceGostin @TomBollyky biocentury.com/article/630376 Image
@davidbeier1747 @LawrenceGostin @TomBollyky The authors 'We argue that two concrete policy steps could go a long way toward establishing public trust in COVID-19 vaccines:full and public disclosure of all data used to justify approval of a vaccine, and the creation of an independent and bipartisan committee to advise FDA.'
@davidbeier1747 @LawrenceGostin @TomBollyky They go on to say: 'We believe that the last chapter of this steeplechase will be whether enough people get vaccinated. Current and expected levels of vaccine hesitancy are far too high to end the pandemic.’
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!